Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients

British Journal of Cancer

Volumn 82, Issue 1, 2000, Pages 171-177

  Ferrero, J M ^a   Etienne, M C ^a   Formento, J L ^a   Francoual, M ^a   Rostagno, P ^a   Peyrottes, I ^a   Ettore, F ^a   Teissier, E ^a   Leblanc Talent, P ^a   Namer, M ^a   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Breast cancer; MDR1; MRP; Multiplex assay; P53

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CELL CYCLE S PHASE; COLORIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033988219     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0896     Document Type: Article

References (32)

1. Abbaszadegan MR, Futscher BW, Klimecki WT, List A and Dalton WS (1994) Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 54: 4676-1679
2. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK and McGuire WL (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206
3. Barrand MA, Heppell-Parlon AC, Wright KA, Rabbits PH and Twentyman PR (1904) A 190-kilodalton protein overexpressed in non-p-glycoprotein-containing multidrug resistant cells and its relationship to the MRP gene. J Natl Cancer Inst 86: 110-117
4. Beck WT, Grogan TM, Willman C and 28 others (1996) Methods in detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56: 3010-3020
5. 1, MRP and LRP gene expression. Br J Cancer 77: 87-91
6. Bloom HJ and Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377
7. Castillo L, Milano G, Santini J, Demard F and Pierrefite V (1997) Analysis of retinoic acid receptor β expression in normal and malignant laryngeal mucosa by a sensitive and routine applicable reverse transcription-polymerase chain reaction enzyme-linked immunosorbent assay method. Clin Cancer Res 3: 2137-2142
8. Chin KV, Ueda K, Pastan I and Gottesman MM (1992) Modulation of activity of the promotor of the human MDR1 gene by ras and p53. Science 255: 459-462
9. Chomezynski P and Sacchi N (1987) Single-step melhod of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Annal Biochem 162: 156-159
10. Dexter DW, Reddy RK, Geles KG, Bansal S, Myint MA, Rogakto A, Leighton JC and Goldstein LJ ( 1998) Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin Cancer Res 4: 1533-1542
11. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339: 71-85
12. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomized trials, Lancet 352 930-942
13. 1 gene expression in primary breast carcinoma. Clin Cancer Res 2: 1231-1237
14. Gasparini G, Pozza F and Harris AL (1993) Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85: 1206-1219
15. lacopetta B, Grieu F, Powell B, Soong R, McCaul K and Seshadri R (1998) Analysis of p53 gene mutation by polymerase chain reaction-single-strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res. 4: 1597-1602
16. Lautier D, Canitrot Y, Deeley RG and Cole SPC (1996) Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52: 967-977
17. Levesque MA, Yu H, Clark GM and Diamandis EP (1998) Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. J Clin Oncol 16: 2641-2650
18. Linn SC, Giaccone G. Van Diest PJ, Blokhuis WMD, Van der Valk P, Van Kalken CK, Kuiper CM, Pinedo HM and Baak JPA (1995) Prognostic relevance of P-glycoprotein expression in breast cancer. Annul Oncol 6: 679-685
19. Lowe SW, Ruley HE, Jacks T and Housman DE (1993) P53-dependent apoptosis modulales the cytotoxicity of anticancer agents. Cell 74: 957-967
20. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T (1994) P53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810
21. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M and Henderson IC (1994) C-erb B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266
22. Namer M, Ramaioli A, Fontana X, Etienne MC, Hery M, Jourlait A, Milano G, Frenay M, François E and Lapalus F (1991) Prognostic value of total cathepsin D in breast tumors. A possible role in selection of chemoresistant patients. Breast Cancer Res Treat 19: 85-93
23. 1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87: 7160-7164
24. Nooter K, Brutel de la Riviere G, Look MP, Van Wingerden KE, Henzen-Logmans SC, Scheper RJ, Flens MJ, Klijn JGM, Stoter G and Foekens JA (1997) The prognostic significance of expression of the multidrug resistance associated protein (MRP) in primary breast cancer. Br J Cancer 76: 486-493
25. Pastan I and Gottesman MM (1987) Multiple-drug resistance in human cancer. N Engl J Med 316: 1388-1393
26. Rayhaud-Diogène H, Télu B, Morency R, Fortin A and Monteil RA (1996) P53 overexpression in head and neck squamous cell carcinoma: review of the literature. Oral Oncol, Eur J Cancer 32B: 143-149
27. Remvikos Y, Beuzedoc P, Zajdela A, Voillemot N, Magdelenat H and Pouillart P (1989) Correlation of pretreatment proliferate activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81: 1383-1387
28. Romain S, Formento JL, Guirou O, Francoual M, Milano G and Martin PM (1994) Determination of oestrogen receptors by enzyme immunoassay. Technical differences between laboratories and their consequences. Eur J Cancer 30: 740-746
29. Scarff RW and Torloni H (1968) Histological typing of breast tumors. Geneva: World Health Organization: 13-20
30. Shimamura A and Fisher DE (1996) P53 in life and death. Clin Cancer Res 2: 435-440
31. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P and Salvadori B (1996) P53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14: 1604-1610
32. Tannock IF (1998) Conventional cancer therapy: promise broken or promise delayed. Lancet 351 (suppl II): 9-16